IGHE and breast cancer: In breast cancer, comparative studies between therapeutic IgG trastuzumab and an engineered trastuzumab IgE antibody recognizing the tumor-antigen HER2 indicated that the IgE counterpart could complement or possibly improve the clinical performance of trastuzumab (Karagiannis et al., 2009).